Holen Sie sich die Stockscreener-App
11.61
7.64%
-0.96
Handel nachbörslich:
11.50
-0.11
-0.95%
Schlusskurs vom Vortag:
$12.57
Offen:
$11.01
24-Stunden-Volumen:
666.80K
Relative Volume:
1.48
Marktkapitalisierung:
$35.13M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+128.94%
1M Leistung:
+160.05%
6M Leistung:
+2.97%
1J Leistung:
+0.00%
1-Tages-Spanne:
$9.71
$12.25
1-Wochen-Bereich:
$5.00
$19.44
52-Wochen-Spanne:
$4.06
$19.44
Traws Pharma Inc Stock (TRAW) Company Profile
Firmenname
Traws Pharma Inc
Sektor
Branche
Telefon
267-759-3680
Adresse
12 PENNS TRAIL, NEWTOWN
Vergleichen Sie TRAW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
11.61 | 35.13M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.18 | 105.12B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.47 | 78.51B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
629.99 | 37.67B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.25 | 31.37B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.13 | 27.36B | 3.30B | -501.07M | 1.03B | -2.1146 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-03-01 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-05-18 | Eingeleitet | Guggenheim | Buy |
| 2018-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2018-01-17 | Herabstufung | Maxim Group | Buy → Hold |
| 2017-10-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-04-27 | Eingeleitet | Laidlaw | Buy |
| 2015-07-01 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Traws Pharma Inc Aktie (TRAW) Neueste Nachrichten
Traws Pharma, Inc. Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu - Marketscreener.com
Nasdaq Surges Over 100 Points, US Durable Goods Orders Decline In November - Benzinga
Traws Pharma Stock Rockets On Promising H5N1 Bird Flu Treatment Results - Benzinga
Stock market news: Direct Digital Holdings +405.45%, Reliance Global Group +214.17% among top gainers during mid day trading - Business Upturn
Stock market news: Direct Digital Holdings up by 363.64% while iLearningEngines down by 70.88% during mid day trading - Business Upturn
Traws Pharma Stock Hits 6-Month Highs On Bird Flu Treatment Breakthrough, Retail Interest Soars - Asianet Newsable
Key pre-market developments in biotech & aerospace - RagingBull
Stock market today: Traws Pharma +231.47%, Rumble +59.02% among top gainers in early trading - Business Upturn
US Stocks Mixed, Dow Tumbles 150 Points - Benzinga
Stock market today: iLearningEngines plunges by 60.44% while Reliance Global Group surged by 231.67% in early trading session - Business Upturn
Traws Pharma Shares Surge 83% on Development of Bird Flu Treatment - MarketWatch
Traws Pharma advances bird flu treatment candidate - Investing.com
Traws Pharma's Bird Flu Drug Shows Breakthrough Results in Phase 1 Trial, Achieves 23-Day Protection - StockTitan
The Most Therapeutic Kind of Me-Time - 69News WFMZ-TV
Traws Pharma announces board member departure By Investing.com - Investing.com Australia
Traws Pharma announces board member departure - Investing.com
Antibiotics Do Not Increase Risks for Cognitive Decline, Dementia in Older Adults, New Data Says - 69News WFMZ-TV
More of America's Pets Are Overdosing on Stray Coke, Meth - 69News WFMZ-TV
Trinity Capital Commits $50M to Form Energy's Revolutionary Iron-Air Battery Manufacturing - StockTitan
Full Stock Market News from 2024-12-14 - StockTitan
Traws Pharma faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada
Traws Pharma faces Nasdaq delisting over equity shortfall - Investing.com
Onconova Therapeutics stock hits 52-week low at $4.37 - Investing.com India
Traws Pharma Faces Uncertain Future Amid Complex Onconova Merger - MSN
Onconova Therapeutics stock hits 52-week low at $4.37 By Investing.com - Investing.com Australia
Onconova Therapeutics, Inc. Announces Management Changes - Marketscreener.com
Traws Pharma Reports Q3 Financials and Updates on Clinical Advances - MSN
Traws Pharma (FRA:0T20) 3-Year EPS without NRI Growth Rate : 25.30% (As of Sep. 2024) - GuruFocus.com
Traws Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Traws Pharma Inc (TRAW) Quarterly 10-Q Report - Quartzy
Traws Pharma Reports Promising Antiviral Drug Progress - TipRanks
Traws Pharma earnings missed by $8.56, revenue topped estimates - Investing.com Canada
Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results - The Manila Times
Traws Pharma Reports Promising Phase 1 Data Despite Widening Q3 Losses | TRAW Stock News - StockTitan
Onconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update - Marketscreener.com
Traws Pharma regains Nasdaq compliance with bid price - Investing.com India
Traws Pharma regains Nasdaq compliance with bid price By Investing.com - Investing.com UK
Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza Treatment - StockTitan
Traws Pharma Inc (TRAW) Q2 2024 Earnings Call Highlights: Navigating Financial Challenges Amid ... - Yahoo Finance
Traws Pharma Reports Positive Phase 1 Results for Influenza Therapy Tivoxavir Marboxil - MyChesCo
Onconova Therapeutics stock hits 52-week low at $4.87 - Investing.com India
Traws Pharma reports positive Phase 1 flu drug results - Investing.com
Traws Pharma reports positive Phase 1 flu drug results By Investing.com - Investing.com Canada
Traws Pharma announces topline Phase 1 data for tivoxavir marboxil - TipRanks
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil - GlobeNewswire
Traws Pharma, Inc. Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil - Marketscreener.com
Onconova Therapeutics stock hits 52-week low at $4.87 By Investing.com - Investing.com Australia
Finanzdaten der Traws Pharma Inc-Aktie (TRAW)
Es liegen keine Finanzdaten für Traws Pharma Inc (TRAW) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.10%
0.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):